Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Xiang Li
 -- 1246 2022-10-12 15:21:18 |
2 format correct
Catherine Yang
 + 3 word(s) 1249 2022-10-13 02:47:18 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Zhao, M.;  Calabretta, R.;  Yu, J.;  Binder, P.;  Hu, S.;  Hacker, M.;  Li, X. Amyloid-Targeting Positron Emission Tomography Imaging. Encyclopedia. Available online: https://encyclopedia.pub/entry/29064 (accessed on 16 November 2024).
Zhao M,  Calabretta R,  Yu J,  Binder P,  Hu S,  Hacker M, et al. Amyloid-Targeting Positron Emission Tomography Imaging. Encyclopedia. Available at: https://encyclopedia.pub/entry/29064. Accessed November 16, 2024.
Zhao, Min, Raffaella Calabretta, Josef Yu, Patrick Binder, Shuo Hu, Marcus Hacker, Xiang Li. "Amyloid-Targeting Positron Emission Tomography Imaging" Encyclopedia, https://encyclopedia.pub/entry/29064 (accessed November 16, 2024).
Zhao, M.,  Calabretta, R.,  Yu, J.,  Binder, P.,  Hu, S.,  Hacker, M., & Li, X. (2022, October 12). Amyloid-Targeting Positron Emission Tomography Imaging. In Encyclopedia. https://encyclopedia.pub/entry/29064
Zhao, Min, et al. "Amyloid-Targeting Positron Emission Tomography Imaging." Encyclopedia. Web. 12 October, 2022.
Amyloid-Targeting Positron Emission Tomography Imaging
Edit
This entry is adapted from the peer-reviewed paper 10.3390/biology11101395

Cardiac amyloidosis (CA) is characterized by extracellular infiltration and deposition of amyloid fibrils primarily derived from the circulating transthyretin protein (TTR) or immunoglobulin light chain (AL). Bone-seeking single-photon emission tomography/computed tomography (SPECT/CT) quantification and amyloid-targeting positron emission tomography (PET) imaging could be useful as a new strategy for disease burden and therapy monitoring to provide more insights into therapy response assessed by quantifying the amyloid burden in CA.

cardiac amyloidosis bone scintigraphy SPECT/CT PET

1. Diagnosis

Bone-seeking radiotracers have revolved primarily around TTR-CA diagnosis while offering a low sensitivity for identifying AL-CA. Targeted amyloid PET imaging has the capability to identify all amyloid deposits regardless of the original protein precursor. Multiple radiotracers for amyloid PET have been investigated in Alzheimer’s disease; these tracers are believed to bind with the beta-pleated motif of the amyloid fibril and have shown promise in clinical research studies, as described in the North American and European expert consensus recommendations for cardiac amyloidosis [1][2]. PET imaging using semi-quantitative parameters (target-to-background ratio) or quantitative metrics (SUV or retention index) has been used in several studies and has demonstrated values for the detection of CA [3]. A meta-analysis including 11C-PIB, 18F-florbetapir, and 18F-florbetaben PET studies showed that the combined sensitivity and specificity for the diagnosis of CA was 95% and 98%, respectively [4][5][6]. A recent study using 18F-flutemetamol PET/MRI or PET/CT showed it to be positive in only 2 of 12 patients with CA, but there was no difference in SUVmax and SUVmean between CA and controls [7]. However, another pilot 18F-flutemetamol study demonstrated a higher number of favorable results (8 out of 9 patients with CA) [8]. Due to the contradictory results, further studies with large sample sizes and appropriate imaging protocols are needed in order better to define the accuracy of 18F-flutemetamol PET imaging in CA.

2. Differentiation between AL and ATTR by PET

To date, only small preliminary studies in vivo utilizing these tracers have highlighted potential benefits in stratifying AL-CA from TTR-CA. The cardiac retention index of 18F-florbetapir tended to be higher in AL patients but was not significantly less in TTR-CA [3]. Subsequently, a similar finding was reported [6] without being able to separate the two CA subtypes by using dynamic PET with 18F-florbetaben in a 20 min scan. These initial findings were also re-observed on 11C-PiB PET imaging [5][9][10]. More recently, a dual-center study demonstrated that 11C-PiB PET imaging had 100% diagnostic accuracy of visual assessment in AL amyloidosis. Moreover, the myocardium to blood SUV ratio was significantly higher in AL than in ATTR patients [11]. However, since 11C-PiB binding to cardiac amyloids has a larger variability in retention index [12], and an on-site cyclotron is required for the production of 11C-labeled radiotracer, 18F-labeled PET tracers with a longer half-life (110 min) may overcome these drawbacks and may be more widely used.
18F-florbetaben PET imaging with a dynamic and delayed acquisition shows a significant increase in uptake in patients with AL compared to those with ATTR or without CA. However, in early studies, there was no difference between AL and TTR amyloidosis patients [13]. In addition, there was virtually no difference in the retention index between TTR and controls. These observations strongly suggested that a late scan obtained at least 30 min after 18F-florbetaben injection can reliably discriminate CA due to AL from either TTR or other mimicking conditions. Notably, because of the non-specific affinity to TTR-CA patients, the application of 18F-florbetaben and PET imaging for the identification of TTR in patients with suspected CA may not be recommended. Furthermore, a dynamic 18F-florbetaben PET study demonstrated that using kinetic model-fitting parameters allows for distinguishing between the two types of amyloid pathology and strengthens the diagnostic accuracy for AL-CA [14]. With the development and application of Deep Learning (DL) techniques in the field of medical imaging, it was reported that a simple DL model derived from cardiac 18F-florbetaben PET images acquired a few minutes after the injection could be used to help clinicians differentiate AL from TTR-CA [15]. Therefore, although the clinical manifestations of AL and ATTR amyloidosis overlap, 18F-florbetaben PET will likely open new avenues as the preferred imaging modality in patients with suspected AL amyloidosis.

3. Prognostic Value

Conventional serum biomarkers such as NT-proBNP and troponin have demonstrated prognostic value in patients with CA, as they indicate cardiac involvement of systemic amyloidosis. However, only a few studies have investigated the role of amyloid-targeting PET in this specific patient group. Recently, Lee SP et al. [5] reported that quantification of myocardial 11C-PiB uptake by PET was associated with adverse outcomes independently among patients with AL-CA. Interestingly, the degree of myocardial 11C-PiB uptake seems to be a better predictor for clinical events such as all-cause death or acute decompensated heart failure than LVEF or diastolic filling parameters (E/e’ ratio) assessed by echocardiography. Furthermore, Choi YJ et al. [16] showed that 11C-PiB PET/CT was not only a strong independent predictor of one year overall survival, but also provided incremental prognostic benefits when combined with commonly used serum biomarkers such as troponin I, NT-proBNP, and dFLC in patients with AL-CA. Given the need for improved cardiac staging systems for prognostication in AL, future prospective studies, possibly multicenter studies, are warranted to discover whether PET/CT should be incorporated into risk stratification for AL amyloidosis patients.

4. Therapy Response Evaluation

Therapy response for AL amyloidosis is normally assessed by hematology (decreased light chains affected and normalization of bone marrow) and organ involvement. For CA, reduction in NT-proBNP by >30% and 300 ng/L (if baseline NT-proBNP ≥ 650 ng/L) is defined as a cardiac response [17]. However, there are drawbacks of solely using natriuretic peptides when they are influenced by other factors (e.g., renal dysfunction, atrial fibrillation and lower body mass index) which are common comorbidities in patients with AL-CA [18]. Thus, imaging biomarkers that reflect a cardiac response could be very useful in detecting changes in structure or function associated with biomarker variation following treatment.
A non-invasive method for detecting and quantifying cardiac amyloid depositions with 18F-florbetapir was evaluated in patients with AL-CA prior to and post-chemotherapy, and its serial utility in monitoring was also assessed [19]. In the three patients with complete hematological response, although no significant difference in cardiac uptake was found between the first and repeated images, there was a suggestion that treatment-naïve patients may have higher cardiac uptake. Given the prospective nature of this study, future studies are needed to include more significant numbers of patients and to assess the optimal time of repeat 18F-florbetapir imaging after treatment. Furthermore, another cardiac 18F-florbetapir PET study consistently showed that all AL patients in that cohort had demonstrable cardiac uptake, despite hematologic remission for more than 1 year [20]. The results offer new insight into the argument of “active” vs. “inactive” amyloid hearts [11], irrespective of serum FLC burden response. In addition to 18F-florbetapir, the use of 18F-florbetaben PET/CT for monitoring anti-inflammatory (AA), anti-myeloma (AL) and TTR-stabilizing (TTR) therapy were also evaluated [21]. The results showed that changes in myocardial tracer retention from baseline to follow-up corresponded well with treatment response.
In summary, the theoretical benefits of amyloid PET in assessing prognosis and monitoring treatment response allow more widespread use in CA. Furthermore, this method will shed much light on a currently opaque and ambiguous assessment process. Nevertheless, it is not yet possible to make reliable statements regarding the incorporation of amyloid PET into the CA-imaging algorithm due to limited data (mostly retrospective) [22], and there are no clinically available PET tracers authorized in the European Union or the United States. Currently, a larger prospective phase III trial evaluating the utility of 18F-florbetaben PET as a diagnostic method for AL-CA is underway (NCT05184088).

References

  1. Dorbala, S.; Ando, Y.; Bokhari, S.; Dispenzieri, A.; Falk, R.H.; Ferrari, V.A.; Fontana, M.; Gheysens, O.; Gillmore, J.D.; Glaudemans, A.; et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J. Nucl. Cardiol. 2019, 26, 2065–2123.
  2. Slart, R.; Glaudemans, A.; Gheysens, O.; Lubberink, M.; Kero, T.; Dweck, M.R.; Habib, G.; Gaemperli, O.; Saraste, A.; Gimelli, A.; et al. Procedural recommendations of cardiac PET/CT imaging: Standardization in inflammatory-, infective-, infiltrative-, and innervation- (4Is) related cardiovascular diseases: A joint collaboration of the EACVI and the EANM: Summary. Eur. Heart J. Cardiovasc Imaging 2020, 21, 1320–1330.
  3. Dorbala, S.; Vangala, D.; Semer, J.; Strader, C.; Bruyere, J.R., Jr.; Di Carli, M.F.; Moore, S.C.; Falk, R.H. Imaging cardiac amyloidosis: A pilot study using (1)(8)F-florbetapir positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 1652–1662.
  4. Kim, Y.J.; Ha, S.; Kim, Y.I. Cardiac amyloidosis imaging with amyloid positron emission tomography: A systematic review and meta-analysis. J. Nucl. Cardiol. 2020, 27, 123–132.
  5. Lee, S.P.; Lee, E.S.; Choi, H.; Im, H.J.; Koh, Y.; Lee, M.H.; Kwon, J.H.; Paeng, J.C.; Kim, H.K.; Cheon, G.J.; et al. 11C-Pittsburgh B PET imaging in cardiac amyloidosis. JACC Cardiovasc Imaging 2015, 8, 50–59.
  6. Law, W.P.; Wang, W.Y.; Moore, P.T.; Mollee, P.N.; Ng, A.C. Cardiac amyloid imaging with 18F-florbetaben PET: A pilot study. J. Nucl. Med. 2016, 57, 1733–1739.
  7. Papathanasiou, M.; Kessler, L.; Carpinteiro, A.; Hagenacker, T.; Nensa, F.; Umutlu, L.; Forsting, M.; Brainman, A.; Kleinschnitz, C.; Antoch, G.; et al. (18)F-flutemetamol positron emission tomography in cardiac amyloidosis. J. Nucl. Cardiol. 2022, 29, 779–789.
  8. Dietemann, S.; Nkoulou, R. Amyloid PET imaging in cardiac amyloidosis: A pilot study using (18)F-flutemetamol positron emission tomography. Ann. Nucl. Med. 2019, 33, 624–628.
  9. Antoni, G.; Lubberink, M.; Estrada, S.; Axelsson, J.; Carlson, K.; Lindsjo, L.; Kero, T.; Langstrom, B.; Granstam, S.O.; Rosengren, S.; et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J. Nucl. Med. 2013, 54, 213–220.
  10. Pilebro, B.; Arvidsson, S.; Lindqvist, P.; Sundstrom, T.; Westermark, P.; Antoni, G.; Suhr, O.; Sorensen, J. Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR). J. Nucl. Cardiol. 2018, 25, 240–248.
  11. Rosengren, S.; Skibsted Clemmensen, T.; Tolbod, L.; Granstam, S.O.; Eiskjaer, H.; Wikstrom, G.; Vedin, O.; Kero, T.; Lubberink, M.; Harms, H.J.; et al. Diagnostic accuracy of PIB positron emission tomography for detection of cardiac amyloidosis. JACC Cardiovasc Imaging 2020, 13, 1337–1347.
  12. Ezawa, N.; Katoh, N.; Oguchi, K.; Yoshinaga, T.; Yazaki, M.; Sekijima, Y. Visualization of multiple organ amyloid involvement in systemic amyloidosis using (11)C-PiB PET imaging. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 452–461.
  13. Genovesi, D.; Vergaro, G.; Giorgetti, A.; Marzullo, P.; Scipioni, M.; Santarelli, M.F.; Pucci, A.; Buda, G.; Volpi, E.; Emdin, M. -florbetaben PET/CT for Differential diagnosis among cardiac immunoglobulin light chain, transthyretin amyloidosis, and mimicking conditions. JACC Cardiovasc Imaging 2021, 14, 246–255.
  14. Santarelli, M.F.; Genovesi, D.; Scipioni, M.; Positano, V.; Favilli, B.; Giorgetti, A.; Vergaro, G.; Landini, L.; Emdin, M.; Marzullo, P. Cardiac amyloidosis characterization by kinetic model fitting on florbetaben PET images. J. Nucl Cardiol 2022, 29, 1919–1932.
  15. Santarelli, M.F.; Genovesi, D.; Positano, V.; Scipioni, M.; Vergaro, G.; Favilli, B.; Giorgetti, A.; Emdin, M.; Landini, L.; Marzullo, P. Deep-learning-based cardiac amyloidosis classification from early acquired pet images. Int J. Cardiovasc Imaging 2021, 37, 2327–2335.
  16. Choi, Y.J.; Koh, Y.; Lee, H.J.; Hwang, I.C.; Park, J.B.; Yoon, Y.E.; Kim, H.L.; Kim, H.K.; Kim, Y.J.; Cho, G.Y.; et al. Independent prognostic utility of (11)C-pittsburgh compound B PET in patients with light-chain cardiac amyloidosis. J. Nucl. Med. 2022, 63, 1064–1069.
  17. Merlini, G.; Lousada, I.; Ando, Y.; Dispenzieri, A.; Gertz, M.A.; Grogan, M.; Maurer, M.S.; Sanchorawala, V.; Wechalekar, A.; Palladini, G.; et al. Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia 2016, 30, 1979–1986.
  18. Ezekowitz, J.A.; Alemayehu, W.; Rathwell, S.; Grant, A.D.; Fiuzat, M.; Whellan, D.J.; Ahmad, T.; Adams, K.; Pina, I.L.; Cooper, L.S.; et al. The influence of comorbidities on achieving an N-terminal pro-b-type natriuretic peptide target: A secondary analysis of the GUIDE-IT trial. ESC Heart Fail. 2022, 9, 77–86.
  19. Manwani, R.; Page, J.; Lane, T.; Burniston, M.; Skillen, A.; Lachmann, H.J.; Gillmore, J.D.; Fontana, M.; Whelan, C.; Hawkins, P.N.; et al. A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement. Amyloid 2018, 25, 247–252.
  20. Ehman, E.C.; El-Sady, M.S.; Kijewski, M.F.; Khor, Y.M.; Jacob, S.; Ruberg, F.L.; Sanchorawala, V.; Landau, H.; Yee, A.J.; Bianchi, G.; et al. Early detection of multiorgan light-chain amyloidosis by whole-body (18)F-florbetapir PET/CT. J. Nucl. Med. 2019, 60, 1234–1239.
  21. Kircher, M.; Ihne, S.; Brumberg, J.; Morbach, C.; Knop, S.; Kortum, K.M.; Stork, S.; Buck, A.K.; Reiter, T.; Bauer, W.R.; et al. Detection of cardiac amyloidosis with (18)F-Florbetaben-PET/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 1407–1416.
  22. Kim, S.H.; Kim, Y.S.; Kim, S.J. Diagnostic performance of PET for detection of cardiac amyloidosis: A systematic review and meta-analysis. J. Cardiol. 2020, 76, 618–625.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Radiology, Nuclear Medicine & Medical Imaging
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Min Zhao
,
Raffaella Calabretta
,
Josef Yu
,
Patrick Binder
,
Shuo Hu
,
Marcus Hacker
,
Xiang Li
View Times: 376
Revisions: 2 times (View History)
Update Date: 13 Oct 2022
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback